[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612037":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":26,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":65,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"whole cohort",null,"Participants who meet the diagnostic criteria for metabolic syndrome, as defined by the International Diabetes Federation (IDF) and\u002For ATP III guidelines and those participants without metabolic syndrome who are matched to the study group by age and sex. These individuals will undergo annual biospecimen collection (blood, urine, and stool) and longitudinal clinical follow-up to identify molecular signatures associated with disease progression and metabolic complications.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"No intervention","no intervention",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Chi-Hsiao Yeh, MD PhD","CONTACT","+886-3-3281200","2118","yehccl@cgmh.org.tw",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Chang Gung Memorial Hospitals, Linkou","RECRUITING","Taoyuan","Taiwan","TW",{"type":34,"coordinates":35},"Point",[36,37],121.29696,24.99368,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":25},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612037","validating-integrative-multi-omics-approaches-in-metabolic-syndrome-related-diseases-100612037",false,"NCT07248371","Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases","Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases: A Step Towards Precision Medicine","Inclusion Criteria:\n\n* Individuals (male or female) aged 20 years or older\n* Willing and able to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis\n* Individuals currently undergoing active cancer treatment\n* Recipients of any organ transplantation\n* Patients diagnosed with dementia","ALL","20 Years",{"count":53,"type":54},6266,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.",[59,60,61,62,63,64],"Metabolic Syndrome (MetS)","Obesity & Overweight","Cardiovascular Diseases (CVD)","Chronic Kidney Disease","Nonalcoholic Fatty Liver Disease","Healthy",[66,67,68,69,70,71,72,73],"Metabolic Syndrome","Multi-Omics","Precision Medicine","Metabolomics","Genomics","Transcriptomics","Microbiome","Machine Learning","2025-11-18",{"date":76,"type":77},"2025-11-25","ACTUAL",{"date":79,"type":77},"2025-06-09",{"date":81,"type":54},"2035-09-30",{"name":5,"class":6},1]